2026 make-or-break for pharma: Pfizer faces patent cliff, pricing and M&A pressures

Pharma earnings flag 2026 as a make-or-break year

Europe’s major drugmakers report mixed quarterly results but emphasise what comes next: 2026 is shaping up as a defining year after a turbulent 2025, with the consequences of last year’s political and commercial moves set to crystallise, industry advisers say. Executives and consultants are focusing less on near‑term beats or misses and more on pipelines, M&A strategies and how governments’ drug‑pricing approaches will affect launches and margins. That shift matters for global competitors such as Pfizer, which faces the same patent‑expiry and growth‑replacement pressures as its European peers.

Industry crossroads for Pfizer as 2026 looms

Pfizer sits at the centre of an industry confronting a looming patent cliff that threatens sales of several best‑selling medicines. Senior consultants tell markets that companies are prioritising business development and late‑stage assets to bridge revenue gaps that internal R&D may not fill in time. In this environment, Pfizer is likely to mirror peers by balancing bolt‑on, early‑stage buys with selective larger acquisitions that can deliver near‑term revenue and pipeline depth, while preserving core R&D investments to sustain long‑term growth.

Executives at rival firms explicitly frame 2026 as the year outcomes of last‑year deals and policy negotiations crystallise, and Pfizer’s commercial planning reflects that timeline. Firms such as Novartis and AstraZeneca are publicly flagging multi‑billion dollar loss‑of‑exclusivity hits and pointing to “strong pipelines” and projected blockbusters to reassure stakeholders; Pfizer is operating under the same industry dynamics and must manage portfolio life‑cycle events, regulatory headwinds and global launch strategies to protect margins. How U.S. and European pricing and regulatory changes are implemented this year will influence whether such measures offset revenues lost to expiring patents.

Sanofi leadership change intensifies sector scrutiny

The abrupt exit of Sanofi’s CEO after a multiyear R&D push that failed to meet expectations underscores the high stakes for large pharma executives. The move highlights the pressure on companies, including Pfizer, to produce tangible clinical and commercial returns from development programs and dealmaking, and signals that boards may demand faster, measurable outcomes.

Policy and dealmaking outlook

Analysts expect 2026 to reveal how prior political agreements and prospective U.S./EU pricing rules affect drug launches, margins and valuations, potentially reshaping M&A appetite across the sector. For Pfizer, the year represents a test of whether a mix of targeted acquisitions, disciplined R&D and global launch execution can offset imminent revenue erosion from expiring exclusivities.